Phase 1 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing to take part voluntarily and sign a consent form agreeing to participate
- You must be 18 years of age or older (any sex)
- You must have previously had a tissue sample (biopsy) confirming you have intermediate or high-risk non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread deep into the bladder wall)
- You must be generally well enough to carry out daily activities with little or no limitation (confirm with trial site)
- Your doctors expect you to live for at least 2 more years
- Your blood counts and organ function (such as liver and kidneys) must be at an acceptable level (confirm with trial site)
Who may not be able to join:
- You have had bladder surgery (such as TURBT) or radiation treatment within the 2 weeks before starting the trial
- You are currently taking part in another clinical trial, or finished one less than 4 weeks before this trial would begin
- You have a history of serious heart or stroke-related conditions
- You have had a severe infection in the 2 weeks before starting the trial
- You still have significant side effects from a previous cancer treatment that have not mostly cleared up (confirm with trial site)
- You have had major surgery or a serious injury within the 4 weeks before starting the trial
- You have previously received certain types of immune-based cancer therapies known as TNFR agonist antibodies (such as OX40, CD137, CD27, or CD357 antibodies)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0518-82342973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose limiting toxicities (DLTs); Maximum tolerated dose (MTD); Incidence and severity of adverse events (AEs) ([CTCAE] v5.0); RP2D（Recommended Phase 2 dose）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.